z-logo
Premium
Addition of low‐dose decitabine to bortezomib and dexamethasone as second‐line therapy in multiple myeloma
Author(s) -
Li Ning,
Liu Lina,
Xiang Pu,
Liang Lijie,
Wang Juan,
Wang Yaomei,
Luo Suxia,
Song Yongping,
Fang Baijun
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16686
Subject(s) - decitabine , lenalidomide , bortezomib , pomalidomide , multiple myeloma , carfilzomib , medicine , oncology , dexamethasone , cancer research , combination therapy , daratumumab , pharmacology , dna methylation , biology , biochemistry , gene expression , gene

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom